A5024039247- Gastric Cancer Management and Outcomes
- Colorectal Cancer Screening and Detection
- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Colorectal and Anal Carcinomas
- Gastrointestinal Tumor Research and Treatment
- Gastrointestinal Bleeding Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
- Folate and B Vitamins Research
- Pharmaceutical studies and practices
- Genetic factors in colorectal cancer
- Nutrition and Health in Aging
- Tuberculosis Research and Epidemiology
- Autoimmune Bullous Skin Diseases
- Congenital gastrointestinal and neural anomalies
- Liver Diseases and Immunity
- COVID-19 Clinical Research Studies
- Palliative Care and End-of-Life Issues
- Digestive system and related health
- Gastrointestinal motility and disorders
- Diverticular Disease and Complications
- Patient Safety and Medication Errors
- Autoimmune and Inflammatory Disorders
- COVID-19 and healthcare impacts
Royal Liverpool University Hospital
2017-2025
University of Liverpool
2017-2025
Royal Liverpool and Broadgreen University Hospital NHS Trust
2018-2024
Broadgreen Hospital
2024
Aintree University Hospitals NHS Foundation Trust
2021
North Tees and Hartlepool NHS Foundation Trust
2015-2016
University of Cumbria
2013
County Durham and Darlington NHS Foundation Trust
2012
Abstract Objectives To quantify post-colonoscopy colorectal cancer (PCCRC) rates in England by using recent World Endoscopy Organisation guidelines, compare incidence among colonoscopy providers, and explore associated factors that could benefit from quality improvement initiatives. Design Population based cohort study. Setting National Health Service between 2005 2013. All people undergoing subsequently diagnosed as having up to three years after their investigation (PCCRC-3yr). Main...
Abstract Background Intravenous [IV] infliximab is a well-established therapy for inflammatory bowel diseases [IBD] patients. A subcutaneous [SC] formulation of [CT-P13] has recently been shown to be as effective IV after two doses induction in randomised trial, but there are no data support elective switching patients on maintenance therapy. We aimed assess the effectiveness an programme SC CT-P13 treated with infliximab. Methods Patients established infliximab, who switched CT-P13, were...
Safety and the avoidance of adverse events are crucial in patient care. A number explanatory variables for serious event colonoscopic perforation have been identified; however, context which occurs has largely overlooked, as too subsequent impact on colonoscopist. This study examined human environmental factors associated with perforations, along colonoscopists' reactions to these, a view informing strategies safer practice clinician support. qualitative explored experiences colonoscopists...
Abstract Background Perforation is the most serious adverse event associated with colonoscopy. In this study of data from English National Health Service Bowel Cancer Screening Programme, we aimed to describe presentation and management perforations, determine factors poorer outcomes post-perforation. Methods The medical records patients a perforation following national screening colonoscopy were retrospectively examined. All colonoscopies performed 02/08/2006 13/03/2014 studied. Centres...
Abstract Background and study aims Colonoscopic polypectomy reduces colorectal cancer incidence, but is associated with complications including post-polypectomy bleeding (PPB). PPB ranges in severity from minor to life-threatening, making interpretation comparison difficult. No previous studies have examined rate according a standardized grading system. We aimed determine the stratified by grading, explore factors that contribute describe management. Methods Data relating were prospectively...
Introduction Antitumour necrosis factor (TNF) agents and vedolizumab are used to treat ulcerative colitis (UC) but the response is variable there little data on comparative effectiveness. Apart from previous exposure anti-TNF agents, predictors of have not been identified. We aimed (i) compare efficacy in UC (ii) investigate utility clinical biochemical parameters predicting response. Patients methods commencing any biological therapy for ambulant were included. Disease activity was...
Objective The 2023 Joint Advisory Group on Gastrointestinal Endoscopy consensus statements colonoscopy training and certification in the UK recommend that trainees should be competent size, morphology, site, access (SMSA) level 2 polypectomy; familiar with classification systems for describing polyps able to handle common intraprocedural complications. Anecdotal concerns expressed by established colonoscopists regarding their own competence relation these new requirements prompted an...
Abstract Background A subcutaneous (SC) formulation of IFX has recently been shown to be as effective intravenous (IV) in a randomised trial but there are no real world data support elective switching. We aimed assess the effectiveness an switching program from IV SC patients with IBD. Methods Patients on maintenance were included this retrospective multi-centre cohort study across two sites. Disease activity was monitored serially Harvey-Bradshaw Index (HBI) and simple clinical colitis...
<h3>Introduction</h3> PCCRC rate is a key quality indicator of colonoscopy. The Word Endoscopy Organisation has reached consensus agreement to use one method for calculating 3 year rates (termed PCCRC-3 y) enable benchmarking rates.<sup>1</sup> This methodology, used previously by Morris et al.<sup>2</sup>, showed y 8.6% across the English National Health Service (NHS) from 2001–2007.<sup>2</sup> with 7.3% in 2007. study aimed determine NHS Bowel Cancer Screening Programme (BCSP)....
<h3>Introduction</h3> Intravenous (IV) infliximab is a well-established therapy for inflammatory bowel diseases (IBD) patients. A subcutaneous (SC) formulation of has recently been shown to be as effective IV in randomised trial but there are no real world data support elective switching. We aimed assess the effectiveness an switching program from SC infliximab. <h3>Methods</h3> Patients on maintenance were included this retrospective multi-centre cohort study across two sites. Disease...
<h3>Introduction</h3> The BSG Guidelines for Osteoporosis in Inflammatory Bowel Disease and Coeliac state there is a definite increased risk of fracture these conditions recommend DEXA scanning after introduction gluten free diet subgroups patients where the osteoporotic high. A 10-year major hip using WHO Fracture Risk Assessment Score (FRAX) can be calculated with coeliac disease this score mapped to National Guideline Group (NOGG) assessment tool may better decide need scan....
Anti-tumour necrosis factor (TNF) agents and vedolizumab are used to treat UC but response is variable there little data on comparative efficacy of these agents. Apart from prior exposure anti-TNF concurrent immunomodulatory therapy, predictors clinical remission biologics have not been identified. We aimed (i) compare the as induction maintenance therapy in (ii) investigate utility routinely biochemical parameters predicting biologics. Patients who were commenced any biological agent for...
<h3>Introduction</h3> Colonoscopies in the English NHSBCSP are offered to 60–74 year olds with an abnormal Faecal Occult Blood Test. Polypectomy breaks adenoma-carcinoma sequence but carries a risk of adverse events such as Post Bleeding (PPB). The has longstanding robust mechanism for capturing and reviewing events. Adverse Events graded by severity using framework, based on American Society Gastrointestinal Endoscopy grading system.<sup>1,2</sup> We aimed (1) determine rate PPB, broken...
<h3>Introduction</h3> Colonoscopic perforation remains one of the most serious adverse events associated with colonoscopy. Colonoscopies in English NHSBCSP are performed at 61 Screening Centres. There is a robust system for capturing details events; patients contacted 24 h and 30 days post procedure, Centres complete an event form, reviewed by regional Quality Assurance leads, entered onto national web based database, Bowel Cancer System (BCSS). We have previously reported rate 0.06%, risk...
<h3>Introduction</h3> Colonoscopic perforation remains one of the most serious adverse events associated with colonoscopy. Patients typically present symptoms as a result peritoneal irritation, however, colonic may be diagnosed radiologically in patients who are entirely asymptomatic. The aims this study were to identify cases asymptomatic detected English NHSBCSP, describe similarities between them and explore why such perforations occur. <h3>Method</h3> We identified all reported...
<h3>Introduction</h3> Perforation is one of the most serious adverse events associated with colonoscopy and may be managed conservatively or surgically. We have previously reported outcomes following colonoscopic perforations in English National Health Service Bowel Cancer Screening Programme, showing that those bowel rest, intravenous fluids antibiotics did not develop post perforation morbidity.<sup>1</sup> therefore aimed to examine which factors could used as indicators for conservative...
<h3>Introduction</h3> Faecal calprotectin is a neutrophil derived protein that can be detected by quantitative enzyme linked immunosorbant assay in stool samples. It reliably predicts the level of mucosal inflammation lower gastrointestinal tract (1). The high negative predictive value faecal should lead to invasive investigation being avoided with subsequent reduction cost and demand on already stretched endoscopy services (2). We reviewed use trust establish if current practise confirms...
<h3>Introduction</h3> Computed tomography colonography (CTC) is the gold standard radiological investigation for colorectal cancer screening. The Post-Imaging Colorectal Cancer (PICRC) rate (i.e. cancers that develop after a negative CTC) key quality indicator of CTC; however, PICRC rates have not been previously reported in national programme. Word Endoscopy Organisation has, through consensus process, agreed methodology calculating to enable international benchmarking (1). This (which WEO...
<h3>Introduction</h3> The success of bowelscope screening (population colorectal cancer aged 55 with a one off flexible sigmoidoscopy) in improving outcomes is reliant on adenoma detection. detection rate has been concern within (BoSS) and national quality asssurance standard set at 6.7%. use Endocuff Vision shown to improve colonoscopy both the Bowel Cancer Screening Programme symptomatic service. There currently randomized controlled trial underway (B-ADENOMA) answer question effectiveness...
<h3>Objective</h3> Intravenous (IV) infliximab (IFX) is a well-established therapy for IBD patients. A subcutaneous (SC) IFX (CT-P13) formulation has recently been shown to be as effective IV in randomised trial but there are no data support elective switching of patients on maintenance therapy. We aimed assess the effectiveness an program SC CT-P13 treated with IFX. <h3>Design</h3> Patients who switched were included this retrospective multi-centre cohort study. Disease activity was...
<h3>Background</h3> A new subcutaneous (SC) formulation of infliximab has recently been approved for the management inflammatory bowel diseases (IBD). In registration clinical trial, efficacy SC IFX was comparable to intravenous (IV) (1) but specific data regarding in perianal Crohn's disease (pCD) is lacking. We aimed investigate patients with pCD who were switched from IV IFX. <h3>Methods</h3> conducted a single centre observational, retrospective study maintained on and Elective switching...